Cytomegalovirus Infection after Prophylactic Valganciclovir Therapy Post-Kidney Transplantation: Case Reports

被引：0
作者：
Nose, K. [1 ]
Oki, T. [1 ]
Banno, E. [1 ]
Nakagawa, M. [1 ]
Sugimoto, K. [1 ]
Nishioka, T. [1 ]
Akiyama, T. [1 ]
机构：
[1] Kinki Univ, Dept Urol, Sakai Hosp, Fac Med,Minami Ku, Sakai, Osaka, Japan
来源：
TRANSPLANTATION PROCEEDINGS | 2012年 / 44卷 / 01期
关键词：
ORAL GANCICLOVIR; DISEASE; RECIPIENTS; OUTCOMES;
D O I：
10.1016/j.transproceed.2011.11.036
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
This report describes three patients who developed cytomegalovirus infection 4 months after high-risk donor+/recipient-(D+/R-) kidney transplantation, despite treatment with valgancyclovir (VGCV) for 3 months at low dose (450 mg/d).
引用
收藏
页码：296 / 298
页数：3
相关论文
共 14 条
  • [1] Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
    Asberg, A.
    Humar, A.
    Rollag, H.
    Jardine, A. G.
    Mouas, H.
    Pescovitz, M. D.
    Sgarabotto, D.
    Tuncer, M.
    Noronha, I. L.
    Hartmann, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) : 2106 - 2113
  • [2] Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients
    Asberg, A.
    Humar, A.
    Jardine, A. G.
    Rollag, H.
    Pescovitz, M. D.
    Mouas, H.
    Bignamini, A.
    Toez, H.
    Dittmer, I.
    Montejo, M.
    Hartmann, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) : 1205 - 1213
  • [3] Cytomegalovirus in Solid Organ Transplant Recipients
    Humar, A.
    Snydman, D.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : S78 - S86
  • [4] Extended Valganciclovir Prophylaxis in D+/R- Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study
    Humar, Atul
    Limaye, Ajit P.
    Blumberg, Emily A.
    Hauser, Ingeborg A.
    Vincenti, Flavio
    Jardine, Alan G.
    Abramowicz, Daniel
    Ives, Jane A. L.
    Farhan, Mahdi
    Peeters, Patrick
    [J]. TRANSPLANTATION, 2010, 90 (12) : 1427 - 1431
  • [5] Effectiveness of Valganciclovir 900 mg versus 450 mg for Cytomegalovirus Prophylaxis in Transplantation: Direct and Indirect Treatment Comparison Meta-analysis
    Kalil, Andre C.
    Mindru, Cezarina
    Florescu, Diana F.
    [J]. CLINICAL INFECTIOUS DISEASES, 2011, 52 (03) : 313 - 321
  • [6] Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial
    Kliem, V.
    Fricke, L.
    Wollbrink, T.
    Burg, M.
    Radermacher, J.
    Rohde, F.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (05) : 975 - 983
  • [7] International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation
    Kotton, Camille N.
    Kumar, Deepali
    Caliendo, Angela M.
    Asberg, Anders
    Chou, Sunwen
    Snydman, David R.
    Allen, Upton
    Humar, Atul
    [J]. TRANSPLANTATION, 2010, 89 (07) : 779 - 795
  • [8] Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis
    Limaye, AP
    Bakthavatsalam, R
    Kim, HW
    Kuhr, CS
    Halldorson, JB
    Healey, PJ
    Boeckh, M
    [J]. TRANSPLANTATION, 2004, 78 (09) : 1390 - 1396
  • [9] Miura M, 2008, TRANSPLANTATION NOW, V21, P109
  • [10] Incidence and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infections in 1244 Kidney Transplant Recipients
    Myhre, Hans-Arne
    Dorenberg, Dagny Haug
    Kristiansen, Knut Ivan
    Rollag, Halvor
    Leivestad, Torbjorn
    Asberg, Anders
    Hartmann, Anders
    [J]. TRANSPLANTATION, 2011, 92 (02) : 217 - 223
12